| Prev Close: | 8.95 |
|---|---|
| Open: | 8.88 |
| Bid: | 7.10 x 200 |
| Ask: | N/A |
| 1y Target Est: | 12.33 |
| Beta: | 1.5 |
| Next Earnings Date: | 5-Aug-13 |
| Day's Range: | 8.51 - 9.30 |
|---|---|
| 52wk Range: | 3.78 - 10.48 |
| Volume: | 164,807 |
| Avg Vol (3m): | 286,226 |
| Market Cap: | 357.21M |
| P/E (ttm): | 99.08 |
| EPS (ttm): | 0.09 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatideat Seeking Alpha(Tue, May 21)
- SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Sun, May 19)
- SUCAMPO PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Due Diligence in Finding the Value of Pharmaceuticals: Expert Portfolio Manager Finny Kuruvilla Discusses His Portfolio Construction Strategy with The Wall Street TranscriptWall Street Transcript(Thu, May 16)
- Sucampo to be Added to the NASDAQ Biotechnology IndexBusiness Wire(Wed, May 15)
- Sucampo Pharmaceuticals to Host Update on AMITIZA® OIC Indication May 20thBusiness Wire(Mon, May 13)
- SUCAMPO PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Sucampo's Stock Could Reach $12, Says Maxim's Senior Vice Presidentat Seeking Alpha(Thu, May 9)
- Sucampo Pharmaceuticals Inc. A Stock Downgraded (SCMP)at TheStreet(Thu, May 9)
- Sucampo's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- Sucampo Pharmaceuticals, Inc Earnings Call scheduled for 5:00 pm ET todayCCBN(Tue, May 7)
- Sucampo Pharmaceuticals, Inc. Reports First Quarter 2013 Financial and Operating ResultsBusiness Wire(Tue, May 7)
- SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD DiscloEDGAR Online(Tue, May 7)
- Q1 2013 Sucampo Pharmaceuticals, Inc Earnings Release - After Market CloseCCBN(Tue, May 7)
- Products with Higher Barriers to Generic Competition Yield Sustained Cash Flows: Expert Analyst David Amsellem Discusses the Brand Specialty Pharma Space with The Wall Street TranscriptWall Street Transcript(Thu, May 2)
Press Releases
- Sucampo to be Added to the NASDAQ Biotechnology IndexBusiness Wire(Wed, May 15)
- Sucampo Pharmaceuticals to Host Update on AMITIZA® OIC Indication May 20thBusiness Wire(Mon, May 13)
Reports
- SCMP: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 22)
- ValuEngine Industry Report for Medical-drugsValuEngine, Inc.(May 22)
- SUCAMPO PHARMACEUTICALS INC (SCMP) - REPORT FOR ACTIVE TRADERSPechala's Reports(May 20)